我們已在上線! 進一步了解
APGN

Apexigen, Inc. Common Stock

已下市

APGN已於2023年8月22日下市。

 

關於: Apexigen Inc is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient's immune system to combat and eradicate cancer.. The company's pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is in clinical development, and also includes several preclinical stage immune-oncology programs.

員工: 31

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於APGN的最新新聞文章。

價格圖表採用Lightweight Charts™實作